Humana Inc
XMUN:HUM
Decide a qué precio te sentirías cómodo comprando y te ayudaremos a estar preparado.
|
H
|
Humana Inc
XMUN:HUM
|
US |
|
CapitaLand Ascott Trust
OTC:ATTRF
|
SG |
|
D
|
Davide Campari Milano NV
F:58H
|
IT |
|
O
|
OMV AG
XMUN:OMV
|
AT |
|
T
|
Tokyu Fudosan Holdings Corp
OTC:TKFOY
|
JP |
|
Biovaxys Technology Corp
F:5LB0
|
CA |
Conferencias de resultados
Última conferencia de resultados
On track: Management said Humana is tracking to expectations for 2026 and remains on course for its 2028 goals, including a sustainable pretax margin of at least 3%.
2027 bids: The company plans meaningful margin expansion in 2027, using benefit changes, plan exits, and ongoing cost improvements to get there.
Stars progress: Humana said its Stars operating improvements are ahead of historical trends, but it still would not predict the final October outcome because CMS thresholds are unknown.
Cost trends: 2026 medical and pharmacy cost trends are still expected to be in the 7% to 8% range, with some favorability in inpatient care.
Efficiency gains: Operating model changes, including centralization and outsourcing, are already producing hundreds of millions of dollars in value this year.
Capital moves: Humana announced a roughly $900 million Gentiva divestiture, $1.5 billion in contingent capital facilities, and a new Illinois Medicaid contract set to begin in January 2027.